Original article Angiomodulators in cancer therapy: New perspectives Lenka Varinska a, 1 , Peter Kubatka b,c, 1, **, Jan Mojzis a , Anthony Zulli d , Katarina Gazdikova e,f, ***, Pavol Zubor c,g , Dietrich Büsselberg h , Martin Caprnda i , Radka Opatrilova j , Iveta Gasparova k , Martin Klabusay l , Martin Pec b , Eitan Fibach m , Mariusz Adamek n , Peter Kruzliak j , * a Department of Pharmacology, Faculty of Medicine, Pavol Jozef Safarik University, Kosice, Slovakia b Department of Medical Biology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia c Division of Oncology, Biomedical Center Martin, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia d The Centre for Chronic Disease, College of Health & Biomedicine, Victoria University, Melbourne, Werribee Campus, Victoria, Australia e Department of Nutrition, Faculty of Nursing and Professional Health Studies, Slovak Medical University, Bratislava, Slovak Republic f Department of General Medicine, Faculty of Medicine, Slovak Medical University, Bratislava, Slovak Republic g Department of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia h Weill Cornell Medicine in Qatar, Qatar Foundation-Education City, Doha, Qatar i 2nd Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia j Department of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Palackeho tr. 1/1946, 612 42 Brno, Czechia k Institute of Biology, Genetics and Medical Genetics, Faculty of Medicine, Comenius University and University Hospital, Bratislava, Slovak Republic l Department of Haemato-Oncology and Department of Internal Medicine – Cardiology, Faculty of Medicine, Palacky University, Olomouc, Czechia m Department of Hematology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel n Department of Thoracic Surgery, Faculty of Medicine and Dentistry, Medical University of Silesia, Katowice, Poland A R T I C L E I N F O Article history: Received 24 November 2016 Received in revised form 3 February 2017 Accepted 20 February 2017 Keywords: Angiogenesis Anti-angiogenics Cancer therapy Marine natural products Galectins microRNAs A B S T R A C T The formation of new blood vessels plays a crucial for the development and progression of pathophysiological changes associated with a variety of disorders, including carcinogenesis. Angiogenesis inhibitors (anti-angiogenics) are an important part of treatment for some types of cancer. Some natural products isolated from marine invertebrates have revealed antiangiogenic activities, which are diverse in structure and mechanisms of action. Many preclinical studies have generated new models for further modification and optimization of anti-angiogenic substances, and new information for mechanistic studies and new anti-cancer drug candidates for clinical practice. Moreover, in the last decade it has become apparent that galectins are important regulators of tumor angiogenesis, as well as microRNA. MicroRNAs have been validated to modulate endothelial cell migration or endothelial tube organization. In the present review we summarize the current knowledge regarding the role of marine-derived natural products, galectins and microRNAs in tumor angiogenesis. © 2017 Elsevier Masson SAS. All rights reserved. Contents 1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 579 2. Marine-derived natural products . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 580 2.1. Bastadin 6 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 580 2.2. Aeroplysinin-1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 581 * Corresponding author. ** Corresponding author at: Department of Medical Biology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Malá Hora 4, 03601 Martin, Slovakia. *** Corresponding author at: Department of Nutrition, Faculty of Nursing and Professional Health Studies, Slovak Medical University, Limbova 12, 833 03 Bratislava, Slovak Republic. E-mail addresses: kubatka@jfmed.uniba.sk (P. Kubatka), katarina.gazdikova@szu.sk (K. Gazdikova), kruzliakpeter@gmail.com (P. Kruzliak). 1 Co-First/Equal authorship. http://dx.doi.org/10.1016/j.biopha.2017.02.071 0753-3322/© 2017 Elsevier Masson SAS. All rights reserved. Biomedicine & Pharmacotherapy 89 (2017) 578–590 Available online at ScienceDirect www.sciencedirect.com